Comparative real-world outcomes of tirzepatide vs semaglutide in patients with obesity and type2 diabetes: A retrospective propensity-matched cohort study

作者
Abdul Qadeer,Marwah Bintay Khalid,Ridwan Syed,Samiksha Jain,Faiza Zakaria,Muhammad Huzaifa Ahmed Khan,Najam Gohar,Ashraf Shoukat,Ibrahim Mortada,Izhan Hamza,Afaq Motiwala,Muhammad Waheed Raja,Thomas A. Blackwell,Hani M. Jneid
出处
期刊:Diabetes and Vascular Disease Research [SAGE Publishing]
卷期号:23 (3): 14791641261465360-14791641261465360
标识
DOI:10.1177/14791641261465360
摘要

BackgroundWith the increasing use of GLP-1 receptor agonists and dual GIP/GLP-1 agonists for managing obesity and type 2 diabetes, understanding their real-world effectiveness and safety is essential. This TriNetX analysis directly compares clinical outcomes among patients treated with tirzepatide vs semaglutide.MethodWe utilized data from the TriNetX Research Network, identifying patients aged > 40 years or with obesity ("BMI ≥ 30 kg/m2") and type 2 diabetes (HbA1c ≥ 6.5% or fasting glucose.≥ 125 mg/dL). Qualifying events were restricted to May 1, 2022, through November 21, 2024. We established two cohorts: one initiating tirzepatide and another semaglutide, ensuring each patient had at least three prescriptions and no prior exposure to the comparator drug or other GLP-1 receptor agonists. The index date was defined as the first co-occurrence of the obesity/diabetes criteria and the respective drug prescription. To ensure comparability, we performed 1:1 propensity matching, resulting in 47,804 patients in each cohort. Outcomes, including all-cause mortality, MACE, heart failure exacerbation, ischemic stroke/TIA, hospitalization/ED use, dementia, UTI, adverse Gastrointestinal (GI) effects, and changes in HbA1c, were assessed within a 1-year window after the index date.ResultsOur matched cohort had a mean age of 75 years, with 45% male patients and 74% identified as white. Patients treated with tirzepatide experienced a significantly lower incidence of MACE at "("3.7% vs 4.1% (RR 0.918, 95% CI 0.862-0.978). All-cause mortality was also lower with tirzepatide (0.2% vs. 0.4%; Risk Ratio 0.436, 95% CI 0.338-0.562). The tirzapetide group achieved better glycemic control with a lower mean HbA1c (6.565% vs. 6.848%; p < 0.001) during the follow-up. There was no significant difference in heart failure exacerbation or UTI incidence. GI side effects were slightly less frequent in the tirzepatide cohort (9.8% vs. 10.2%; Risk Ratio 0.959, 95% CI 0.924-0.997), while hospitalization or emergency visits were comparable between the two groups.ConclusionIn this propensity matched cohort of patients with obesity and type 2 diabetes, tirzepatide demonstrated improved cardiometabolic outcomes compared to semaglutide, including lower all-cause mortality and lower HbA1c. These findings support the cardiovascular safety and efficacy of tirzapetide and highlight the need for further studies to evaluate its effectiveness in broader clinical populations.
最长约 10秒,即可获得该文献文件

科研通智能强力驱动
Strongly Powered by AbleSci AI
科研通是完全免费的文献互助平台,具备全网最快的应助速度,最高的求助完成率。 对每一个文献求助,科研通都将尽心尽力,给求助人一个满意的交代。
实时播报
Jia完成签到 ,获得积分10
刚刚
活佛济公完成签到 ,获得积分10
1秒前
程11完成签到,获得积分10
1秒前
负责谷秋完成签到 ,获得积分10
4秒前
ncuwzq完成签到,获得积分0
4秒前
Lliu完成签到,获得积分10
8秒前
么么完成签到,获得积分10
13秒前
饿哭了塞完成签到 ,获得积分10
13秒前
我不会乱起名字的完成签到,获得积分10
13秒前
吴旭东完成签到,获得积分10
16秒前
16秒前
gycao2025完成签到,获得积分10
17秒前
刘艺涵完成签到 ,获得积分10
17秒前
Einy完成签到 ,获得积分10
17秒前
MoChin完成签到,获得积分10
17秒前
acat完成签到 ,获得积分10
18秒前
温暖完成签到 ,获得积分10
19秒前
zc完成签到,获得积分10
20秒前
Tin完成签到,获得积分10
21秒前
hh完成签到 ,获得积分10
21秒前
刻苦绿蕊完成签到,获得积分10
23秒前
李伟完成签到,获得积分10
23秒前
Sure完成签到 ,获得积分10
23秒前
曾珍完成签到 ,获得积分10
26秒前
青云万里完成签到,获得积分10
26秒前
142857完成签到,获得积分10
28秒前
Una2030完成签到 ,获得积分10
32秒前
轻松香菇完成签到 ,获得积分10
33秒前
Jeffrey完成签到,获得积分10
34秒前
房杨完成签到,获得积分10
34秒前
七七完成签到 ,获得积分10
35秒前
怡然铭完成签到 ,获得积分10
36秒前
黄芪完成签到,获得积分10
40秒前
高山流水完成签到,获得积分10
41秒前
lingling00完成签到 ,获得积分10
42秒前
山野的雾完成签到 ,获得积分10
43秒前
沉静梦蕊完成签到,获得积分10
47秒前
枯叶灬风发布了新的文献求助10
49秒前
微笑完成签到,获得积分10
49秒前
myyyyy完成签到,获得积分10
50秒前
高分求助中
(应助此贴封号)【重要!!请各用户(尤其是新用户)详细阅读】【科研通的精品贴汇总】 10000
拉伸高分子熔体中缠结行为的模拟和小角中子散射研究 1700
The World Atlas of Wine 9th edition 1000
奈特基础组织学:配套组织病理学(第4版)(Netter's Essential Histology With Correlated Histopathology) 800
John McDowells Bildungstheorie 800
Social Psychology in the Real World 600
八旗制度の研究 600
热门求助领域 (近24小时)
化学 材料科学 医学 生物 纳米技术 计算机科学 工程类 有机化学 化学工程 生物化学 物理 复合材料 内科学 催化作用 光电子学 人工智能 细胞生物学 无机化学 物理化学 数学
热门帖子
关注 科研通微信公众号,转发送积分 8180097
求助须知:如何正确求助?哪些是违规求助? 9570230
关于积分的说明 21808841
捐赠科研通 7776113
什么是DOI,文献DOI怎么找? 3433261
关于科研通互助平台的介绍 2557463
邀请新用户注册赠送积分活动 2479013